www.indiainfoline.com - Dec 07, 2010

Marck has acquired the assets of Goa-based Ravish Infusion on a lock-stock-barrel basis for a total sum of Rs. 547 Lakhs under auction process from Debt Recovery Tribunal II, Mumbai.
Marck Biosciences Ltd., India’s leading manufacturer and marketer of sterile liquids pharmaceutical dosages using the Blow-Fill-Seal (BFS) technology has acquired a large volume injectible facility in Goa and will step up its manufacturing capacity for large volume injectibles by over 33% by March 2011. 

Marck has acquired the assets of Goa-based Ravish Infusion on a lock-stock-barrel basis for a total sum of Rs. 547 Lakhs under auction process from Debt Recovery Tribunal II, Mumbai. Marck has also signed an MoU with Coimbatore based Paragon Steels Pvt Ltd. (Gujarat Inject Kerala Limited) for purchase of its injectibles equipment for Rs. 150 Lakhs. Marck plans to set up these equipments at the Goa facility.

Bhavesh Patel, MD, Marck Biosciences said, “The estimated total global market size for injectibles was approximately USD 140 billion in 2009. Marck Biosciences is operating above 90% capacity since last 3 years in large volume injectibles. The acquisitions will help Marck Biosciences expand capacity to meet the growing demand. With these two acquisitions, the total capacity for large volume injectibles will increase by 200 Lakhs bottles per year.”

Presently at its 18.40   acres facility at Kheda in Gujarat, Marck has an installed capacity to manufacture Large Volume Parenterals  of 596 Lakhs bottles p.a. as well as pr Small Volume Parenterals of 2265 Lakhs vials p.a.

The Goa facility will enable Marck to manufacture Large Volume Parenterals having Euroheads, which Company proposes to market in South East Asia, East & West Africa and CIS countries. Marck is one of the versatile manufacturers in BFS space, and offers different closure systems, such as nipple head, twist-off, leur-lock & screw types and container fill-volume ranging from  0.5  ml to 1000 ml. Marck exports to around 77 countries and during the financial year 2009-10 about 31% of Marck’s total sales was supplied to export markets.

Marck has recently filed a Draft Red Herring Prospectus for Public Issue of 1,30,00,000 equity shares of face value Rs. 10/- each through book building process. Marck plans to utilize the partly net proceeds of the IPO for setting up a sterile liquid manufacturing plant, for fluid therapy & formulations and partly for corporate needs and partly for Issue expenses. The facility is intended to be built to WHO cGMP specifications and will enhance Marck’s capacity by an additional 462 lakhs bottles per annum.

Marck Biosciences is a rapidly growing Sterile Liquid Pharmaceutical Company engaged in Formulation & Development, Manufacturing and Marketing in India and approximately 77 countries across 6 continents.

Marck Biosciences manufacture and market around 80 therapeutic and non therapeutic products. Its therapeutic product groups comprise of Formulations, Fluid Therapy, Injections, Ophthalmics and Respiratory Care. Marck’s manufacturing facilities comprises of five Aseptic Blow Fill Seal (ABFS) manufacturing lines and one Aspectic Conventional Plastic Bottle Filling line.

Marck Biosciences have developed the capability to comply with regulatory audits of MHRA (UK), TGA (Australia) and MCA (South Africa) and get their approval. The Company has already received approvals from ANVISA (Brazil) & NPCB (Malaysia – a PIC member country) for the small volume parenterals facility. 

Marck have also got ‘CE Mark’ approval from SGS for its non therapeutic segment products. CE Mark approval allows Marck to market its products in USA, UK and Australia. The Manufacturing facilities at Kheda are ISO: 9001-2000, ISO: 13485, ISO 14001: 2004, OHSAS 18001:2007 and WHO-GMP certified.